

1           **Inflammatory biomarkers in pregnant women with COVID-19: a retrospective cohort study**

2           Andrea Lombardi<sup>1\*</sup>, Silvia Duiella<sup>2</sup>, Letizia Li Piani<sup>2</sup>, Ferruccio Ceriotti<sup>3</sup>, Massimo Oggioni<sup>3</sup>, Antonio  
3           Muscatello<sup>1</sup>, Alessandra Bandera<sup>1,4</sup>, Andrea Gori<sup>1,4</sup>, Enrico Ferrazzi<sup>2</sup>

4           <sup>1</sup>*Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy;* <sup>2</sup>*Unit*  
5           *of Obstetric, Dept of Woman Child and Neonate, Foundation IRCCS Ca' Granda Ospedale Maggiore*  
6           *Policlinico, Mangiagalli Centre, University of Milan, Italy;* <sup>3</sup>*Clinical Laboratory, Foundation IRCCS Ca'*  
7           *Granda Ospedale Maggiore Policlinico, Milano, Italy;* <sup>4</sup>*University of Milan, Department of Pathophysiology*  
8           *and Transplantation, Milan, Italy.*

9           **\*Corresponding author:** Andrea Lombardi, MD, Infectious Diseases Unit, Foundation IRCCS Ca' Granda  
10          Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy. Telephone: 0039-02-55034767 E-  
11          mail: [andrea.lombardi@policlinico.mi.it](mailto:andrea.lombardi@policlinico.mi.it) ORCID: 0000-0002-0383-9579

12 **Abstract**

13 Coronavirus disease 2019 is a pandemic viral disease affecting also obstetric patients and uncertainties exist  
14 about the prognostic role of inflammatory biomarkers and hemocytometry values in patients with this infection.  
15 To clarify that, we assessed the values of several inflammatory biomarkers and hemocytometry variables in a  
16 cohort of obstetric patients hospitalized with coronavirus disease 2019 and we correlated the values at admission  
17 with the need of oxygen supplementation during the hospitalization. Overall, among 27 (61%) pregnant women  
18 and 17 (39%) post-partum women, 6 (14%) patients received oxygen supplementation and 2 (4%) required  
19 admission to intensive care unit but none died. During hospitalization neutrophils ( $p=0.002$ ), neutrophils to  
20 lymphocytes ratio ( $p=0.037$ ) and C reactive protein ( $p<0.001$ ) decreased significantly, whereas lymphocytes  
21 ( $p<0.001$ ) and platelets ( $p<0.001$ ) increased. Leukocytes and lymphocytes values at admission were correlated  
22 with oxygen need, with respectively a 1% and 5% higher risk of oxygen supplementation for each 1,000 cells  
23 decrease. Overall, in obstetric patients hospitalized with coronavirus disease 2019, C reactive protein is the  
24 inflammatory biomarker that better mirrors the course of the disease whereas D-dimer or ferritin are not reliable  
25 predictors of poor outcome. Care to the need of oxygen supplementation should be reserved to patients with  
26 reduced leukocytes or lymphocytes values at admission.

27 **Keywords:** pregnancy; coronavirus disease 2019; SARS-CoV-2; inflammatory biomarkers

## 28 **Introduction**

29 The pandemic of coronavirus disease 2019 (COVID-2019), caused by the severe acute respiratory syndrome  
30 coronavirus 2 (SARS-CoV-2), is affecting many women during pregnancy and in the postpartum worldwide.  
31 According to the available data, the severity of the disease seems comparable between pregnant women and  
32 non-pregnant women.<sup>1</sup> In addition to its impact on the cardio-pulmonary physiology, pregnancy is characterized  
33 by several shifts in the woman immunologic profile. Particularly, in preparation of delivery, a pro-inflammatory  
34 state occurs with immune cells migrating into the myometrium and high levels of pro-inflammatory cytokines  
35 found both in the cervical tissue and in the peripheral blood.<sup>2</sup> Unfortunately, a peculiar characteristic of COVID-  
36 19 is the release of a large amount of inflammatory cytokines, a condition that in severe cases resembles the  
37 macrophages activation syndrome.<sup>3</sup> Some inflammatory biomarkers have been considered as tools to monitor  
38 the evolution of COVID-19, namely C reactive protein (CRP), lactate dehydrogenase (LDH), ferritin and D-  
39 dimer.<sup>4-6</sup> Also alterations of the leukocytes count, such as lymphocytopenia or an elevated neutrophils to  
40 lymphocytes ratio (NLR), seems correlated with disease severity.<sup>7,8</sup>

41 Unfortunately, the role of the above-mentioned markers has not been studied during pregnancy and in the  
42 postpartum in women infected by SARS-CoV-2. We do not know their evolution during the disease and  
43 whether their values can be adopted at admission to guide clinical choices. In this retrospective cohort of  
44 obstetric patients admitted with COVID-19 at our tertiary referral centre, we assessed the baseline values and  
45 the trend of inflammatory biomarkers and hemocytometry variables and their association with the severity of  
46 COVID-19.

## 47 **Results**

### 48 *Demographic and clinical characteristics*

49 We enrolled 44 women. At discharge, 27/44 patients (61%) were still pregnant, whereas 17/44 (39%) delivered  
50 during the hospitalization. The median gestational age at admission was 34 weeks and 3 days. Overall, no death  
51 occurred in our cohort, 9 (20%) patients required oxygen supplementation, and only 2 (4%) patients were  
52 admitted to the intensive care unit (ICU). In both cases for acute pulmonary embolism leading to respiratory  
53 insufficiency in patients not receiving prophylaxis with enoxaparin. Pregnant women had lower mean body  
54 mass index ( $p=0.007$ ) and gestational age ( $p<0.001$ ) compared with those who delivered who instead reached  
55 the virologic cure in a longer period ( $p=0.03$ ) and reported more frequently coryza as symptom ( $p=0.009$ ). Since  
56 March 30, 2020, all patient (26/44, 63%) started at admission prophylactic enoxaparin at the dosage of 100

57 IU/Kg daily. Immunomodulatory therapy with hydroxychloroquine 200 mg every 12 hours was started in those  
58 with lung involvement at chest x-ray (18/44, 41%). Table 1 shows the clinical and demographic characteristics  
59 of the patients enrolled.

#### 60 *Inflammatory biomarkers and white blood cells trend during hospitalization*

61 At admission, the median lymphocytes values were below the lower reference limit (1,200 cells/ $\mu$ L). Instead,  
62 the median values of NLR, C reactive protein, D-dimer, procalcitonin and fibrinogen were all above the upper  
63 reference limits (3.53, 0.5 mg/dL, 500  $\mu$ g/L, 0.06  $\mu$ g/L and 350 mg/dL, respectively). During the observation  
64 time neutrophils (p=0.002), NLR (p=0.037) and CRP (p<0.001) values decreased whereas lymphocytes  
65 (p<0.001) and platelets (p<0.001) increased. Table 2 summarizes inflammatory biomarkers and white blood  
66 cells trend during hospitalization. The results of multiple comparisons tests performed to assess differences  
67 among the same variable at different timepoints are shown in figure 1.

#### 68 *Predictors of oxygen need*

69 The independent effect of different variables at baseline on the likelihood of receiving oxygen supplementation  
70 was interrogated by a univariate logistic regression analysis and the results are reported in table 3. The model  
71 proved to be significant for leukocytes and lymphocytes and explained 20% and 43% (Nagelkerke R<sup>2</sup>) of the  
72 variance for each variable, respectively. Reduced leukocytes and lymphocytes values were associated with an  
73 increased likelihood of oxygen supplementation. Two multiple logistic regression models were then built,  
74 including in model A leukocytes, CRP and D-dimer and in model B lymphocytes, CRP and D-dimer. Both  
75 leukocytes and lymphocytes lost their association with oxygen supplementation in the multivariate model.

#### 76 **Discussion**

77 Our findings show how, among the variables assessed in our study, CRP was the only inflammatory biomarkers  
78 which varied significantly during the course of COVID-19 in obstetric patients and thus could be employed to  
79 monitor the evolution of the disease. Among hemocytometry parameters, neutrophils, lymphocytes, platelets,  
80 and neutrophils-to-lymphocytes ratio are those with values which changed significantly. Considering their  
81 widespread availability in any hospitalized patient, they also could be employed in assessing disease  
82 progression. Interestingly, low leukocytes or lymphocytes values at admission were associated with a higher  
83 likelihood of receiving oxygen supplementation during hospitalization, suggesting that additional care should be  
84 reserved to patients presenting with reduced values of these blood cells.

85 Our findings agree with the result of previous studies highlighting how COVID-19 patients are characterized by  
86 a relevant systemic inflammation, which acts as a driver of morbidity and mortality. Particularly,  
87 lymphocytopenia<sup>8</sup>, a high NLR<sup>9</sup> and high values of CRP<sup>10</sup> had all been linked with disease severity or mortality.  
88 Our work confirms that these variables show abnormal values also in obstetric patients and mirrors the course of  
89 the disease.

90 Intriguingly, D-dimer values, despite being well above the upper reference limit, were not associated with  
91 oxygen need and did not vary significantly during the hospitalization. A mounting amount of evidence is  
92 supporting the role of vascular endothelialitis and thrombosis in the pathogenesis of COVID-19<sup>11,12</sup>, and D-  
93 dimer values above 1,000 µg/L have been associated with a poor prognosis.<sup>13</sup> In our cohort D-dimer values were  
94 above this limit in all the timepoints. It is possible that the administration of antithrombotic prophylaxis with  
95 enoxaparin in more than half of the patients have prevented some additional thromboembolic events. Moreover,  
96 it should be recognized that pregnancy is characterized by a physiologic increase of D-dimer values, especially  
97 in the third trimester.<sup>14,15</sup> Therefore, in the specific setting of pregnant women, D-dimer values do not seem a  
98 reliable prognostic tool.

99 To our surprise ferritin values were well above those observed in normal pregnancies,<sup>16</sup> which is characterized  
100 by a physiologic anaemic state and where high levels of ferritin, especially in the third trimester, are associated  
101 with negative outcomes (e.g. preterm delivery and gestational diabetes).<sup>17</sup> At the same time, our values were  
102 well below those observed in several cohorts of non-pregnant COVID-19 patients.<sup>18</sup> For example, Chen and  
103 colleagues observed a median ferritin of 337 µg/L among their patients with moderate COVID-19.<sup>6</sup> Therefore, it  
104 is possible to speculate that the inflammatory status caused by SARS-CoV-2 leads to an increase of serum  
105 ferritin also in obstetric patients, but this increase is partially concealed by the low levels of this molecule  
106 physiologically encountered in this population.

107 When compared to similar cohorts of obstetric patients with COVID-19, we have a striking similarity in terms  
108 of displayed symptoms. Fever, cough and dyspnoea were the three most frequently reported symptoms also in  
109 the large British UKOSS (UK Obstetric Surveillance System) cohort and in two Italian cohorts.<sup>19-21</sup>

110 Interestingly, we have found that the severity of COVID19 in pregnant women or in the post-partum was  
111 inferior to that previously reported in the literature. Indeed, we did not observe any death and admission to the  
112 ICU was required in only two patients. Instead, Di Mascio and colleagues described in their systematic review a  
113 mortality rate of 11.4% and a rate of ICU admission of 31.4%.<sup>22</sup> Results comparable to ours are observed in

114 several cohorts of obstetric patients with COVID-19 in different regions of the world. Probably these data are  
115 more representative of the real-life clinical scenario, being the results provided by Di Mascio *et al.* from a  
116 systematic review based on early cases reported in the literature, which usually are those more severe or  
117 unusual. New systematic assessments of morbidity and mortality in obstetric COVID-19 patients are needed.

118 Finally, we observed a longer period of time to reach virologic cure in women who delivered during the  
119 hospitalization compared with women who did not. This can be the consequence of a mere methodologic issue.  
120 Indeed, per protocol women in the puerperal period were hospitalized for a minimum of 5 days after birth to  
121 monitor the new-born. Virologic tests were planned in both groups at 14 days after hospital discharge.  
122 Therefore, this difference in time to virologic cure could be only the consequence of a longer permanence in the  
123 hospital, even though women in the post-partum did not present a statistically significant longer hospitalization  
124 compared to pregnant women. To understand if this difference in viral shedding is real, possibly influenced by  
125 different hormonal condition between advanced pregnancy versus earlier phases, a stricter follow-up with  
126 repeated molecular assessment of SARS-CoV-2 presence is required.

127 We recognize that our work has some limitations. First, is a single centre study, and therefore the conclusions  
128 can apply only to the specific population afferent to the hospital in which the study was performed. Considering  
129 that our hospital was the referring centre for obstetric patients with COVID-19 of a large portion of Lombardy  
130 region, the most populous Italian region, and the large variation in ethnicities taken in care, we can suggest that  
131 this element did not impact the results. Second, it is a retrospective study, and some analysis (i.d. surveillance  
132 nasal swab) were performed for clinical/epidemiologic reasons and not to ascertain biologic differences, as  
133 stated above.

134 Based on the results of our study, a minimum set of analyses composed of hemocytometry plus CRP should be  
135 performed in obstetric patients with COVID-19 at admission and during hospitalization, to assess disease  
136 severity and follow the evolution of the disease. Specific care to oxygen need should be reserved to those  
137 patients presenting with low values of leukocytes and lymphocytes at admission.

## 138 **Methods**

### 139 *Study population*

140 We enrolled a cohort of pregnant women consecutively admitted at the COVID-19 Maternity Hub at the  
141 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy with a diagnosis of COVID-19 in

142 the period from March 10, 2020 to April 24, 2020. Clinical and demographic data were extracted from the  
143 electronic medical records.

144 The diagnosis of COVID-19 was established by the detection of SARS-CoV-2 in a nasopharyngeal swab. The  
145 nasopharyngeal swab was performed either, in all pregnant women admitted for obstetric indication, or in  
146 women with at least one of the following signs or symptoms: fever, cough, dyspnoea, asthenia, myalgia, coryza,  
147 sore throat, headache, ageusia or dysgeusia, anosmia or parosmia, ocular symptoms, diarrhoea, nausea, and  
148 vomit. All SARS-CoV-2 positive cases were admitted in a dedicated COVID-19 ward. Inflammatory  
149 biomarkers and hemocytometry variables were assessed at admission, at 48 hours and 96 hours after admission  
150 and at discharge. The execution of chest x-ray or chest computed tomography (CT) was reserved to patients  
151 with respiratory symptoms, according to clinical judgment. The patients enrolled were subdivided in two groups  
152 according delivery during hospitalization or not.

153 Clinical cure was defined as the absence of fever, a respiratory rate <22 breaths per minutes and peripheral  
154 haemoglobin saturation values >95% for at least three days. All patients repeated two nasopharyngeal swabs at  
155 an interval of 24 hours, 14 days after discharge or 14 days after clinical cure if still hospitalized for other  
156 reasons. If both the swabs resulted negative the patient was considered cured (virologic cure) of the infection  
157 and not requiring anymore isolation measures.

#### 158 *Pro-inflammatory biomarkers assessment and white blood cell profile*

159 Procalcitonin (PCT) and ferritin were measured with electrochemiluminescent immunoassays (ECLIA) on a  
160 Roche Cobas e801 instrument (Roche Diagnostics, Monza, Italy). C-reactive protein (CRP) was measured with  
161 an immunoturbidimetric method and lactate dehydrogenase (LDH), alanine and aspartate aminotransferase  
162 (ALT, AST) with the International Federation of Clinical Chemistry (IFCC) optimized methods on a Roche  
163 Cobas c702 instrument (Roche Diagnostics, Monza, Italy). Fibrinogen and D-dimer were measured with ACL  
164 Top (Werfen, Milano, Italy). Hemocytometry analysis was performed with Sysmex XN 9000 (Dasit, Cornaredo,  
165 Italy).

#### 166 *SARS-CoV-2 detection*

167 Two different methods were used for viral detection. The first one consisted in Seegene Inc reagents (Seoul,  
168 Korea), RNA extraction with STARMag Universal Universal Cartridge kit on Nimbus instrument (Hamilton,  
169 Agrate Brianza, Italy) and amplification with Allplex® 2019-nCoV assay, while the second employed a

170 GeneFinder® COVID-19 Plus RealAmp Kit (OSANG Healthcare, Anyangcheonong-ro, Dongan-gu, Anyang-  
171 si, Gyeonggi-do, Korea) on ELITech InGenius® instrument (Torino, Italy). Both assays identify the virus by  
172 multiplex rRT-PCR targeting three viral genes (E, RdRP and N).

173 *Statistical analysis and ethics*

174 Descriptive statistics were obtained for all the variables reported for this study. Groups were compared with  
175 unpaired t test or Mann-Whitney test and Fisher's exact test. The trend of different variables during  
176 hospitalization was assessed with Friedmann test and Dunn's multiple comparisons test. Univariate logistic  
177 regression models were employed to assess correlation between variables at baseline and oxygen  
178 supplementation. Multivariate logistic regression models were then built including significant variables at  
179 univariate analysis and variables with a biologic correlate. A  $p$  value  $<0.05$  was deemed statistically significant.  
180 All the analysis was performed with SPSS Statistics 23 (IBM Corp, USA). The study was approved by the  
181 Institutional Review Board (#339\_2020) and conducted according to the Declaration of Helsinki. An informed  
182 consent was obtained from all the patients enrolled.

183 *Data availability*

184 All data will be available on request.



## 185 References

- 186 1. Blitz, M. J. *et al.* Intensive Care Unit Admissions for Pregnant and Non-Pregnant Women with COVID-  
187 19. *Am. J. Obstet. Gynecol.* (2020). doi:10.1016/j.ajog.2020.05.004
- 188 2. Bränn, E., Edvinsson, Å., Rostedt Punga, A., Sundström-Poromaa, I. & Skalkidou, A. Inflammatory and  
189 anti-inflammatory markers in plasma: from late pregnancy to early postpartum. *Sci. Rep.* **9**, 1–10 (2019).
- 190 3. Schulert, G. S. & Grom, A. A. Pathogenesis of Macrophage Activation Syndrome and Potential for  
191 Cytokine- Directed Therapies. *Annu. Rev. Med.* **66**, 145–159 (2015).
- 192 4. Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-  
193 Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* **323**, 1061–1069 (2020).
- 194 5. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus  
195 pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513 (2020).
- 196 6. Chen, G. *et al.* Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J.*  
197 *Clin. Invest.* (2020). doi:10.1172/jci137244
- 198 7. Liu, J. *et al.* Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel  
199 Coronavirus in the Early Stage. *medRxiv* **807**, 2020.02.10.20021584 (2020).
- 200 8. Lombardi, A. *et al.* Baseline profile COVID-19 Early phases of COVID-19 are characterized by a  
201 reduction of lymphocyte populations and the presence of atypical monocytes. *medXriv* (2020).
- 202 9. Liu, Y. *et al.* Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized  
203 patients with COVID-19. *J. Infect.* (2020). doi:10.1016/j.jinf.2020.04.002
- 204 10. Zhu, Z. *et al.* Clinical value of immune-inflammatory parameters to assess the severity of coronavirus  
205 disease 2019. *Int. J. Infect. Dis.* **95**, 332–339 (2020).
- 206 11. Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.  
207 *N. Engl. J. Med.* NEJMoa2015432 (2020). doi:10.1056/NEJMoa2015432
- 208 12. Martinelli, I. *et al.* Pulmonary embolism in a young pregnant woman with Covid-19. *Thromb. Res.*  
209 (2020). doi:10.1016/j.jns.2019.116544
- 210 13. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in  
211 Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062 (2020).
- 212 14. Gutiérrez García, I. *et al.* D-dimer during pregnancy: establishing trimester-specific reference intervals.  
213 *Scand. J. Clin. Lab. Invest.* **78**, 439–442 (2018).
- 214 15. Murphy, N. *et al.* Gestation-specific D-dimer reference ranges: A cross-sectional study. *BJOG An Int. J.*  
215 *Obstet. Gynaecol.* **122**, 395–400 (2015).
- 216 16. Daru, J., Allotey, J., Peña-Rosas, J. P. & Khan, K. S. Serum ferritin thresholds for the diagnosis of iron  
217 deficiency in pregnancy: a systematic review. *Transfus. Med.* **27**, 167–174 (2017).
- 218 17. Scholl, T. O. Iron status during pregnancy: Setting the stage for mother and infant. *Am. J. Clin. Nutr.* **81**,  
219 1218–1222 (2005).
- 220 18. Li, Y., Hu, Y., Yu, J. & Ma, T. Retrospective analysis of laboratory testing in 54 patients with severe- or  
221 critical-type 2019 novel coronavirus pneumonia. *Lab. Investig.* (2020). doi:10.1038/s41374-020-0431-6
- 222 19. Savasi, V. M. *et al.* Clinical Findings and Disease Severity in Hospitalized Pregnant Women With  
223 Coronavirus Disease 2019 (COVID-19). *Obstet. Gynecol.* **00**, 1–7 (2020).
- 224 20. Ferrazzi, E. *et al.* Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a  
225 retrospective analysis. *BJOG* **24**, 1–6 (2020).
- 226 21. Dphil, M. K., Mbchb, N. S., Gale, C. & Knight, M. Characteristics and outcomes of pregnant women  
227 hospitalised with confirmed SARS-CoV-2 infection in the UK a national cohort study using the UK  
228 Obstetric Surveillance System (UKOSS). *Medrxiv* 1–22 (2020). doi:10.1101/2020.05.08.20089268

- 229 22. Mascio, D. Di *et al.* Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during  
230 pregnancy: a systematic review and meta-analysis. *Am. J. Obstet. Gynecol. MFM* **2**, 100107 (2020).  
231

232 **Funding:** none related to the content of this article.

233 **Conflict of interest:** none related to the content of this article.

234 **Authors contributions** AL, EF, AB and AG designed the study. SD and LLP collected the data. AL performed  
235 the analysis and wrote the first draft of the manuscript. All the authors revised the final version of the  
236 manuscript.

237 **Acknowledgments** The authors are thankful to Valeria Castelli for the help in data collection.

238 **Figure legend**

239 **Figure 1** Leukocytes (**a**), neutrophils (**b**), lymphocytes (**c**), neutrophils to lymphocytes (NLR) ratio (**d**), platelets  
240 (**e**), C reactive protein (**f**), fibrinogen (**g**), D-dimer (**h**) and ferritin (**i**) assessed at admission, at 48 and 96 hours  
241 from admission and at discharge. \* denotes statistically significant differences ( $p < 0.005$ )

242 **Table 1** Demographic and clinical characteristics of obstetric patients with COVID-19. Among pregnant women  
 243 are included those patients who did not deliver during hospitalization, among post-partum women those who  
 244 did. All data are expressed as median and interquartile range or numbers and percentages except when stated  
 245 otherwise. \*mean (SD) (BMI: body mass index; LMWH: low-molecular-weight heparin; CPAP: continuous  
 246 positive airways pressure; ICU: intensive care unit)

	All (n=44)	Pregnant women (n=27)	Post-partum women (n=17)	p
Age (years)*	29.9 (5.8)	30 (6.6)	29.8 (4.5)	ns
Ethnicity				
Caucasic	19 (43%)	15 (55%)	4 (23%)	ns
Black	2 (4%)	0	2 (12%)	ns
Hispanic	11 (25%)	7 (26%)	4 (23%)	ns
Arab	12 (27%)	5 (18%)	7 (41%)	ns
BMI*	27.3 (5)	25.9 (4.8)	30.1 (4.5)	<b>0.007</b>
Gestational age at admission (weeks+days)	34+3 (27-38+0-5)	28+4 (26-31+0-4)	37+7 (34.5-39+0-4)	<b>&lt;0.001</b>
Time since symptoms (days)	4 (2-6)	3.5 (1.2-5.7)	4 (2-6)	ns
Hospitalization length (days)	9 (6-18)	8 (6-16)	10 (5.5-21.5)	ns
Time for clinical cure (days)	6 (4-8.5)	6 (3.2-8)	8 (4-11.5)	ns
Time for virologic cure (days)	25 (21-30)	23.5 (21-27.2)	30 (21.2-34.7)	<b>0.03</b>
Chest X-ray/Chest computed tomography	33 (75%)	20 (74%)	13 (76%)	ns
Reduced transparency/Ground glass	13 (29%)	6 (30%)	7 (41%)	ns
Interstitial thickening/Crazy paving	17 (39%)	8 (40%)	9 (53%)	ns
Consolidation	12 (27%)	7 (35%)	5 (30%)	ns
Therapy	30 (68%)	20 (74%)	10 (59%)	ns
Lopinavir/Ritonavir	1 (2%)	0	1 (6%)	ns
Hydroxychloroquine	18 (41%)	12 (44%)	6 (35%)	ns
LMWH	26 (53%)	18 (67%)	8 (47%)	ns
Oxygen supplementation	9 (20%)	5 (18%)	4 (23%)	ns
Symptoms	28 (64%)	15 (55%)	13 (76%)	ns
Fever	20 (45%)	10 (37%)	10 (59%)	ns
Dyspnoea	10 (23%)	6 (22%)	4 (23%)	ns
Cough	20 (45%)	12 (44%)	8 (47%)	ns
Coryza	7 (16%)	1 (4%)	6 (35%)	<b>0.009</b>
Asthenia	3 (7%)	2 (7%)	1 (6%)	ns
Anosmia/ageusia	1 (2%)	1 (4%)	0	ns
Nausea/diarrhoea	1 (2%)	1 (4%)	0	ns
Pharyngitis	4 (9%)	2 (7%)	2 (12%)	ns

247

248 **Table 2** Values (median and interquartile range) of inflammatory biomarkers and hemocytometry variables at  
 249 different study timepoints. NLR: neutrophils to lymphocytes ratio; LDH: lactate dehydrogenase; AST: aspartate  
 250 aminotransferase; ALT: alanine aminotransferase.

	<b>Admission</b>	<b>48 hours</b>	<b>96 hours</b>	<b>Discharge</b>	<b>p</b>
Leukocytes (cells/mL)	7,790 (5,168-9,405)	7,790 (5,168-9,405)	7,150 (5,633-8,640)	6,735 (5,508-8,563)	ns
Neutrophils (cells/mL)	5,650 (4,595-7,730)	5,810 (3,110-6,785)	4,770 (3,540-6,185)	4,290 (3,425-5,480)	<b>0.002</b>
Lymphocytes (cells/mL)	1,180 (1,000-1,830)	1,675 (1,128-2,008)	1,545 (1,305-2,058)	1,675 (1,400-2,145)	<b>&lt;0.001</b>
Platelets (10 <sup>3</sup> cells/mL)	220 (175-271)	225 (189-282)	257 (196-342)	299 (218-396)	<b>&lt;0.001</b>
NLR	4.4 (3.7-5.1)	3.1 (2.2-5)	2.9 (2.2-4.4)	2.8 (2.3-3.6)	<b>0.037</b>
Ferritin (µg/L)	38 (27-99)	56 (34-98)	67 (28-142)	51 (24-126)	ns
C reactive protein (mg/dL)	2.7 (1.4-5.4)	1.9 (1-4.7)	1.1 (0.3-3.7)	0.4 (0.2-1.7)	<b>&lt;0.001</b>
D-dimer (µg/L)	1,642 (1,298-2,323)	1,329 (984-1,898)	1,310 (1,037-1,518)	1,422 (1,079-1,852)	ns
Procalcitonin (µg/L)	0.08 (0.05-0.1)	0.08 (0.04-0.1)	0.06 (0.04-0.12)	0.05 (0.03-0.09)	ns
Fibrinogen (mg/dL)	450 (399-557)	462 (421-540)	485 (397-550)	430 (365-525)	ns
LDH (U/L)	187 (149-236)	179 (141-228)	203 (162-273)	177 (152-263)	ns
AST (U/L)	43 (24-50)	32 (13-68)	55 (45.5-104)	24 (19-45)	ns
ALT (U/L)	18 (13-22)	18 (12-25)	18 (13-28)	20 (15-35)	ns

251

252 **Table 3** Simple logistic regression and multiple logistic regression models for oxygen supplementation at  
 253 baseline. In the multivariate logistic regression model A were included leukocytes, CRP and D-dimer, in model  
 254 B lymphocytes, CRP and D-dimer. NLR: neutrophils to lymphocytes ratio; CRP: C reactive protein; PCT:  
 255 procalcitonin; CI: confidence interval.

	Simple logistic regression		Multiple logistic regression			
	Odds ratio (95%CI)	p	Model A		Model B	
Odds ratio (95%CI)			p	Odds ratio (95%CI)	p	Odds ratio (95%CI)
Leukocytes	0.999 (0.999-1)	<b>0.044</b>	1 (1-1)	0.99		
Neutrophils	0.913 (0.654-1.167)	ns				
Lymphocytes	0.995 (0.990-1)	<b>0.037</b>			1 (0.999-1.01)	0.09
NLR	1.171 (0.912-1.533)	ns				
CRP	0.993 (0.890-1.024)	ns	1.01 (0.950-1.07)	0.79	0.966 (0.888-1.05)	0.41
PCT	1.643 (0.905-12.110)	ns				
Fibrinogen	1.002 (0.996-1.009)	ns				
D-dimer	0.998 (0.995-1)	ns	1 (0.99-1.01)	0.15	1 (0.999-1.01)	0.16
Haemoglobin	0.910 (0.531-1.561)	ns				
Ferritin	0.998 (0.975-1.022)	ns				

256

